ArticleTranslational lung cancer research2026

Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol).

Shuaiyi Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.